This company listing is no longer active
Codiak BioSciences Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 3.2yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Brokers Are Upgrading Their Views On Codiak BioSciences, Inc. (NASDAQ:CDAK) With These New Forecasts
Nov 08
Codiak BioSciences drops 31% postmarket on proposed stock offering
Sep 12Codiak cuts 37% of staff amid plans to reprioritize studies
Aug 30Codiak begins dosing in early-stage trial for liver, gastric, colorectal cancers
Jun 29Broker Revenue Forecasts For Codiak BioSciences, Inc. (NASDAQ:CDAK) Are Surging Higher
Mar 15Codiak BioSciences, Inc. (NASDAQ:CDAK) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Insider Buying: The Codiak BioSciences, Inc. (NASDAQ:CDAK) Independent Director Just Bought US$100k Worth Of Shares
Feb 18
What Percentage Of Codiak BioSciences, Inc. (NASDAQ:CDAK) Shares Do Insiders Own?
Jan 14CEO
Codiak BioSciences has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Scientific Officer | 2.1yrs | US$1.41m | 0% $ 0 | |
| Treasurer | 7.6yrs | US$1.57m | 0% $ 0 | |
| VP of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior Vice President of Human Resources | 3.2yrs | no data | 0.013% $ 7.8 |
Experienced Management: CDAK.Q's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 3.7yrs | US$197.87k | no data | |
| Independent Chairman of the Board | 7.7yrs | US$228.50k | no data | |
| Independent Director | 6yrs | US$192.87k | 0.024% $ 14.0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 2.3yrs | US$19.21k | no data | |
| Independent Director | 4.4yrs | US$184.75k | no data | |
| Independent Director | 2.2yrs | US$243.57k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 1.1yrs | US$27.46k | no data | |
| Independent Director | 2.9yrs | US$197.25k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: CDAK.Q's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/11 14:42 |
| End of Day Share Price | 2023/07/06 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Codiak BioSciences, Inc. is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maneka Mirchandaney | Evercore ISI |
| Graig Suvannavejh | Goldman Sachs |
| David Nierengarten | Wedbush Securities Inc. |